Análise do impacto da similaridade farmacocinética dos inibidores da bomba de prótons

A widely used therapeutic class and with many drugs are proton pump inhibitors (PPIs), which act by inhibiting the secretion of hydrochloric acid in the intestinal lumen in the parietal cell by means of the proton pump, thereby preventing acidification of the Stomach Ph, and thus promoting the increase in Ph. The study was carried out in order to investigate the pharmacokinetic differences between proton pump inhibitors (PPIs) and whether these differences really justify the development of new drugs. This study is characterized as a documentary research, with a quantitative and analytical-discursive approach, carried out through Micromedex solutions®, an international scientific platform used by health professionals in the clinic for the safe management of patient therapy. Dexlansoprazole and esomeprazole are the most superior differences in medication compared to the others. On the other hand, pantoprazole and omeprazole are the drugs that have shorter activities. The cost-benefit, similarity and quantity of PPIs lead us to believe that the total amount of PPIs present on the market with quite similar characteristics, presumably, without pharmacological purposes, may be unnecessary. It is unnecessary from the pharmacokinetic and pharmacological point of view the high range of drugs produced for the same purpose, since not all of them have enough differences to be placed on the market.